Keyphrases
Israel
82%
Aspergillus Fumigatus
41%
Invasive Aspergillosis
40%
Red Blood Cell Aggregation
35%
Candida Albicans (C. albicans)
29%
BNT162b2 Vaccine
28%
Mucormycosis
27%
Candida Auris
25%
Bacterial Infection
25%
Voriconazole
24%
COVID-19
24%
Virulence
23%
Bloodstream Infection
23%
Extended-spectrum-lactamase
23%
Aurès
22%
Invasive Fungal Disease
22%
Enterobacteriaceae
22%
Candidemia
21%
Pseudomonas Aeruginosa (P. aeruginosa)
21%
Multidrug-resistant
21%
Healthcare Workers
20%
Invasive Candidiasis
20%
Risk Factors
19%
Confidence Interval
19%
Bacteremia
18%
Clinical Outcomes
18%
Red Blood Cells
17%
Pseudomonas Aeruginosa Bacteraemia
17%
Posaconazole
17%
Echinocandins
16%
Fluconazole
16%
Candida
16%
Monotherapy
16%
Angiogenesis
16%
Third Dose
16%
Fumigatus
15%
Single Center
15%
Odds Ratio
15%
Antifungal Therapy
15%
Antibiotic Treatment
14%
Randomized Controlled Trial
14%
Combination Therapy
14%
Immunocompromised Patients
14%
Israeli
14%
Prospective Cohort Study
14%
Fly Model
13%
Fever
13%
Candida Glabrata
13%
Azole Resistance
13%
Carbapenems
12%
Pharmacology, Toxicology and Pharmaceutical Science
Infection
79%
Antifungal Agent
40%
Antibiotics
36%
Cohort Study
33%
Disease
31%
Pseudomonas aeruginosa
31%
Invasive Aspergillosis
30%
Bloodstream Infection
30%
Mould
24%
Bacteremia
24%
Mucormycosis
21%
Candida
20%
Fluconazole
20%
Bacterial Infection
18%
Combination Therapy
17%
Enterobacteriaceae
17%
Candidemia
17%
Aspergillus fumigatus
17%
Antiinfective Agent
15%
Invasive Candidiasis
15%
Monotherapy
14%
Fibrinogen
14%
Retrospective Study
14%
COVID-19 Vaccine
14%
Adverse Event
12%
Antifungal Therapy
11%
Hematologic Malignancy
11%
Voriconazole
11%
Posaconazole
11%
Clinical Feature
11%
Carbapenem
10%
Mortality Rate
10%
Penicillinase
10%
Aspergillus
10%
Antibiotic Therapy
10%
Extended Spectrum Beta Lactamase
10%
Randomized Controlled Trial
9%
Candida Auris
9%
Infectious Agent
9%
Piperacillin Plus Tazobactam
9%
Chimeric Antigen Receptor
9%
Vaccination Policy
9%
Antibiotic Agent
8%
Clostridium Difficile Infection
8%
Bacteriophage
8%
Candida Albicans
8%
Pneumocystis Jiroveci
8%
Gaucher's Disease
8%
Feces microflora
8%
Febrile Neutropenia
8%
Medicine and Dentistry
Infection
100%
COVID-19
28%
Antifungal Agent
28%
Disease
23%
Pseudomonas aeruginosa
23%
Bloodstream Infection
22%
Mucormycosis
21%
Antibiotic Therapy
19%
Health Care
19%
Bacteremia
19%
Penicillinase
18%
Extended Spectrum Beta Lactamase
17%
Enterobacteriaceae
17%
Odds Ratio
17%
Mycosis
16%
Antibiotics
15%
Pathogen
14%
Retrospective Study
14%
Randomized Controlled Trial
14%
Severe Acute Respiratory Syndrome Coronavirus 2
13%
Blood Culture
13%
Combination Therapy
13%
Hematologic Malignancy
12%
Invasive Aspergillosis
11%
Candidemia
11%
Clinical Feature
11%
Carbapenem
11%
Mortality Rate
10%
Human Immunodeficiency Virus
10%
Retrospective Cohort Study
10%
Arm
10%
Extended Spectrum Beta Lactamase Producing Enterobacteriaceae
10%
Fungal Infection
9%
Fluconazole
9%
Monotherapy
9%
Systemic Candidiasis
9%
Systemic Mycosis
9%
Brain Abscess
8%
Bacterial Infection
8%
Piperacillin/Tazobactam
8%
Cohort Analysis
8%
Clostridium Difficile Infection
8%
Men Who Have Sex with Men
8%
Cat-Scratch Disease
8%
Fecal Microbiota Transplantation
8%
Bacteriophage
8%
Compassionate Use
8%
Pneumocystis Jirovecii
8%
Malignant Neoplasm
8%
Cross Sectional Study
8%